Interna

[Comment] Plasma biomarkers for Alzheimer's disease among middle-aged individuals

VIP article

Alzheimer's disease has a long preclinical phase in which neuropathological changes, such as amyloid β (Aβ) and tau pathology, accumulate over many years.1 This preclinical phase provides an opportunity for earlier disease detection and interventions to prevent or delay dementia. Emerging blood-based biomarkers provide

ME

MedScopeGlobal Editorial

May 29, 2026

InternaVIP

Evidence-based clinical briefing

[Comment] Plasma biomarkers for

MedScope VIP

This article is reserved for VIP subscribers. Upgrade for full access, an ad-free reading experience, and priority clinical alerts.

View membership options

Doporučený obsah